1. Ates O, Cayli SR, Gurses I, et al. Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury. J Clin Neurosci. 2007. 14:658–665.
Article
2. Baptiste DC, Fehlings MG. Pharmacological approaches to repair the injured spinal cord. J Neurotrauma. 2006. 23:318–334.
Article
3. Basso DM, Beattie MS, Bresnahan JC. Graded histological and locomotor outcomes after spinal cord contusion using the NYU weight-drop device versus transection. Exp Neurol. 1996. 139:244–256.
Article
4. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med. 1990. 322:1405–1411.
5. Bradbury EJ, Moon LD, Popat RJ, et al. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature. 2002. 416:636–640.
Article
6. Deckner M, Lindholm T, Cullheim S, Risling M. Differential expression of tenascin-C, tenascin-R, tenascin/J1, and tenascin-X in spinal cord scar tissue and in the olfactory system. Exp Neurol. 2000. 166:350–362.
Article
7. Domeniconi M, Cao Z, Spencer T, et al. Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth. Neuron. 2002. 35:283–290.
Article
8. Fawcett JW, Asher RA. The glial scar and central nervous system repair. Brain Res Bull. 1999. 49:377–391.
Article
9. Frisén J, Haegerstrand A, Risling M, et al. Spinal axons in central nervous system scar tissue are closely related to laminin-immunoreactive astrocytes. Neuroscience. 1995. 65:293–304.
Article
10. Huang CS, Song JH, Nagata K, Yeh JZ, Narahashi T. Effects of the neuroprotective agent riluzole on the high voltage-activated calcium channels of rat dorsal root ganglion neurons. J Pharmacol Exp Ther. 1997. 282:1280–1290.
11. Ikegami T, Nakamura M, Yamane J, et al. Chondroitinase ABC combined with neural stem/progenitor cell transplantation enhances graft cell migration and outgrowth of growthassociated protein-43-positive fibers after rat spinal cord injury. Eur J Neurosci. 2005. 22:3036–3046.
Article
12. Jones LL, Margolis RU, Tuszynski MH. The chondroitin sulfate proteoglycans neurocan, brevican, phosphacan, and versican are differentially regulated following spinal cord injury. Exp Neurol. 2003. 182:399–411.
Article
13. Jones LL, Sajed D, Tuszynski MH. Axonal regeneration through regions of chondroitin sulfate proteoglycan deposition after spinal cord injury: a balance of permissiveness and inhibition. J Neurosci. 2003. 23:9276–9288.
Article
14. Kaneko S, Iwanami A, Nakamura M, et al. A selective Sema3A inhibitor enhances regenerative responses and functional recovery of the injured spinal cord. Nat Med. 2006. 12:1380–1389.
Article
15. Kikuchi K, Kishino A, Konishi O, et al. In vitro and in vivo characterization of a novel semaphorin 3A inhibitor, SM-216289 or xanthofulvin. J Biol Chem. 2003. 278:42985–42991.
Article
16. Lee HH, Yang JY, Lee JK. The impact of combined treatments with aminoguanidine and methylprednisolone on neurological recovery after spinal cord injury. J Korean Orthop Assoc. 2007. 42:444–452.
Article
17. Lemons ML, Howland DR, Anderson DK. Chondroitin sulfate proteoglycan immunoreactivity increases following spinal cord injury and transplantation. Exp Neurol. 1999. 160:51–65.
Article
18. Liou AK, Clark RS, Henshall DC, Yin XM, Chen J. To die or not to die for neurons in ischemia, traumatic brain injury and epilepsy: a review on the stress-activated signaling pathways and apoptotic pathways. Prog Neurobiol. 2003. 69:103–142.
Article
19. Matsumoto T, Tamaki T, Kawakami M, Yoshida M, Ando M, Yamada H. Early complications of high-dose methylprednisolone sodium succinate treatment in the follow-up of acute cervical spinal cord injury. Spine. 2001. 26:426–430.
Article
20. Morgenstern DA, Asher RA, Fawcett JW. Chondroitin sulphate proteoglycans in the CNS injury response. Prog Brain Res. 2002. 137:313–332.
21. Mu X, Azbill RD, Springer JE. Riluzole improves measures of oxidative stress following traumatic spinal cord injury. Brain Res. 2000. 870:66–72.
Article
22. Nógrádi A, Szabó A, Pintér S, Vrbová G. Delayed riluzole treatment is able to rescue I njured rat spinal motoneurons. Neuroscience. 2007. 144:431–438.
23. Plant GW, Bates ML, Bunge MB. Inhibitory proteoglycan immunoreactivity is higher at the caudal than the rostral Schwann cell graft-transected spinal cord interface. Mol Cell Neurosci. 2001. 17:471–487.
Article
24. Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci. 2004. 5:146–156.
Article
25. Sun W, Gould TW, Newbern J, et al. Phosphorylation of c-Jun in avian and mammalian motoneurons in vivo during programmed cell death: an early reversible event in the apoptotic cascade. J Neurosci. 2005. 25:5595–5603.
Article
26. Yang JY, Daniel RK. Agonist for the control of apoptosis through the study of cytokine expression after spinal cord injury in Rats. J Korean Orthop Assoc. 2007. 42:106–114.
27. Yang JY, Kim HS, Lee JK. Changes in nitric oxide synthase expression in young and adult rats after spinal cord injury. Spinal Cord. 2007. 45:731–738.
Article
28. Yang JY, Lee JK, Kim KT, Lee HH, Byun BN, Ahn SH. The expression and function of the tumor necrosis factor receptor I (TNFRI), TNFRII, and X-linked inhibitor of apoptosis genes after spinal cord injury in rats. J Korean Soc Spine Surg. 2004. 11:14–23.
Article
29. Yin KJ, Kim GM, Lee JM, He YY, Xu J, Hsu CY. JNK activation contributes to DP5 induction and apoptosis following traumatic spinal cord injury. Neurobiol Dis. 2005. 20:881–889.
Article